SYK and cancer: Similar results were observed in another two tested models, one model involving MET-amplified MKN45 cancer cells with stable SYK knockdown and one model involving EGFR-mutant PC9 cells with stable SYK knockdown (Fig. 1i and Supplementary Fig. S3d).